tirzepatide cardiovascular outcomes trial results july 2025 event risk assessment: a pre-specified meta-analysis Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular
Description
Friedman is advising his patients to make a 10-minute followup appointment to discuss options
Patients should use non-oral contraceptives or a backup method for 4 weeks after initiation and after each dose escalation
Here's what it means, why it's happening, and what your options are going forward
For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively
For a look at how semaglutide results compare, TrimRx has a detailed breakdown of semaglutide timelines as well
